James Staman, MD
Ophthalmology · Jacksonville, FLNPI 1841290657
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (48.3%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 81.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $1,798 and has fallen 87.7% since, to $222 in 2025.
Across 25 payments — averaging $137.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$3K
- Harrow Eye, LLC$154
- Astellas Pharma US Inc$115
- Halozyme Inc$72
- Novartis$67
- Sight Sciences, Inc.$56
- plus $186 from 8 others
What the payments were for
- Food & beverage$64919%
- Ownership interest$1,13033%
- Other$1,66348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $2,792 |
| Harrow Eye, LLC | 1 | $154 |
| Astellas Pharma US Inc | 1 | $115 |
| Halozyme Inc | 4 | $72 |
| Novartis | 4 | $67 |
| Sight Sciences, Inc. | 1 | $56 |
| Lumibird Medical Inc. | 1 | $42 |
| Sun Pharmaceutical Industries Inc. | 1 | $26 |
| Carl Zeiss Meditec USA, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Boston Scientific | 1 | $21 |
| AbbVie | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Spark Therapeutics, Inc. | 1 | $14 |
How this compares
$3,441 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 185 | $462,114 |
| Eylea HdAflibercept | 58 | $170,625 |
| VabysmoFaricimab-Svoa | 36 | $79,497 |
| LucentisRanibizumab | 17 | $44,857 |
| Prednisolone Acetate | 411 | $21,915 |
| RhopressaNetarsudil Mesylate | 30 | $12,302 |
| LumiganBimatoprost | 14 | $7,778 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,289 |
| Ketorolac Tromethamine | 179 | $5,207 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $4,699 |
| Brimonidine Tartrate | 291 | $4,166 |
| Atropine Sulfate | 114 | $3,801 |
| Brinzolamide | 13 | $3,641 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $3,571 |
| Latanoprost | 366 | $3,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $25 | $632,739243 claims |
| Genentech USA, Inc.Vabysmo | $14 | $79,49736 claims |
| AbbVieLumigan, Combigan | $17 | $13,06725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.